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Abstract
Background Information is lacking on long-term management of patients with acute coronary syndrome (ACS) and chronic 
kidney disease (CKD) (estimated glomerular filtration rate [eGFR] < 60 mL/min/1.73  m2).
Objectives Our objectives were to describe antithrombotic management patterns and outcomes in patients with ACS with 
varying renal function from the EPICOR (long-tErm follow-uP of antithrombotic management patterns In acute CORonary 
syndrome patients; NCT01171404) and EPICOR Asia (NCT01361386) studies.
Methods EPICOR and EPICOR Asia were prospective observational studies of patients who survived hospitalization for 
ACS and were enrolled at discharge in 28 countries across Europe, Latin America, and Asia. The studies were conducted 
from 2010 to 2013 and from 2011 to 2014, respectively. This analysis evaluated patient characteristics and oral antithrom-
botic management patterns and outcomes up to 2 years post-discharge according to admission eGFR: ≥ 90, 60–89, 30–59, 
or < 30 mL/min/1.73  m2.
Results Among 22,380 patients with available data, eGFR < 60 mL/min/1.73  m2 was observed in 16.7%. Patients with 
poorer renal function were older, were at greater cardiovascular risk, and had more prior cardiovascular disease and bleed-
ing. Patients with CKD underwent fewer cardiovascular interventions and had more in-hospital cardiovascular and bleeding 
events. Dual antiplatelet therapy was less likely at discharge in patients with eGFR < 30 (82.3%) than in those with ≥ 90 
(91.3%) mL/min/1.73  m2 and declined more sharply during follow-up in patients with low eGFR (p < 0.0001). An adjusted 
proportional hazards model showed that patients with lower eGFR levels had a higher risk of cardiovascular events and 
bleeding.
Conclusions The presence of CKD in patients with ACS was associated with less aggressive cardiovascular management 
and an increased risk of cardiovascular events.
 * Yong Huo 
 huoyong@263.net.cn
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1 Introduction
Chronic kidney disease (CKD) is associated with an 
increased risk of cardiovascular disease (CVD), and patients 
with CKD presenting with an acute coronary syndrome 
(ACS), particularly those with more severe renal dysfunc-
tion, have higher rates of mortality, complications, and 
bleeding events [1–6]. According to data from the National 
Cardiovascular Data Acute Coronary Treatment and Inter-
vention Outcomes Network (ACTION) registry in the USA, 
CKD (defined as estimated glomerular filtration rate [eGFR] 
< 60 mL/min/1.73  m2) is present in approximately 43% of 
patients presenting with non-ST-segment elevation (NSTE)-
ACS (including NSTE myocardial infarction [NSTEMI] and 
unstable angina) and 31% of those with ST-segment eleva-
tion myocardial infarction (STEMI) [4].
Given the poorer prognosis for those with CKD, and the 
potential need for dose adjustment of some antithrombotic 
agents, guidelines recommend that eGFR be evaluated as 
soon as possible in patients presenting with ACS [7, 8]. 
However, the same guidelines offer little in the way of treat-
ment guidance for patients with CKD because of the pau-
city of solid evidence in this regard as patients with severe 
renal dysfunction have been systematically excluded from 
many randomized clinical trials [9, 10]. There is evidence 
indicating that outcomes are better in patients with CKD 
who undergo early revascularization [11–13] and receive 
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Key Points 
Data from EPICOR and EPICOR Asia, twin interna-
tional observational studies with a 2-year follow-up 
period, showed that chronic kidney disease (estimated 
glomerular filtration rate < 60 mL/min/1.73  m2) was 
associated with less aggressive management and an 
increased risk of cardiovascular events and bleeding, 
across all three types of acute coronary syndromes 
(ACS) (ST-segment elevation myocardial infarction 
[STEMI], non-STEMI, and unstable angina).
Patients with ACS and renal dysfunction require careful 
assessment and tailored short- and long-term antithrom-
botic management to reduce adverse clinical event rates.
hospitalized within 24 h (EPICOR) or 48 h (EPICOR Asia) 
of symptom onset. For the present analysis, patients were 
also required to have a known level of renal function, defined 
by eGFR.
All patients were enrolled at discharge from hospital, 
which could be the original center to which they were 
admitted or another participating hospital to which they 
were transferred. Patients transferred to a non-participating 
hospital (and not transferred back again) were therefore 
excluded from the study. Other key exclusion criteria were 
“secondary” ACS (that is, precipitated by or occurring as 
a complication of surgery, trauma, percutaneous coronary 
intervention [PCI], or other reasons), any serious or severe 
comorbidities considered likely to limit life expectancy to 
less than 6 months, and prior enrollment in EPICOR or EPI-
COR Asia.
2.2  Objectives
The primary objective of EPICOR and EPICOR Asia was 
to describe acute and long-term AMPs in ACS survivors in 
a wide range of clinical settings and countries [20, 21]. The 
objectives of the present analysis were to describe patient 
characteristics, oral AMPs, and clinical outcomes over the 
2-year follow-up period in patients with one of four different 
categories of renal function at hospital admission (baseline), 
defined as eGFR ≥ 90, 60–89, 30–59, or < 30 mL/min/1.73 
 m2. eGFR was calculated using the 2009 Chronic Kidney 
Disease Epidemiology Collaboration creatinine formula 
[22]:
 where κ is 0.7 for females and 0.9 for males, α is − 0.329 for 
females and − 0.411 for males, and sCr is serum creatinine.
In this report, CKD is defined as patients with eGFR< 60 
mL/min/1.73 m2.
2.3  Baseline and In‑Hospital Variables
Collected variables included baseline demographic data, 
socio-economic factors, medical history (including prior 
CVD and non-CVD), major bleeding events within 6 
months prior to the index event, medications, procedures 
(PCI and coronary artery bypass graft [CABG]), labora-
tory test results, and EuroQol 5-Dimensions (EQ-5D) 
simple score for quality of life. Data on medication, proce-
dures, and outcomes (cardiovascular and bleeding events) 
during initial hospitalization were also recorded, as were 





= 141 ×min (sCr∕, 1) ×max (sCr∕, 1)−1.209
× 0.993Age × (1.018 if female),
prolonged dual antiplatelet therapy (DAPT) during follow-
up [14], but recent studies have suggested that they are 
largely undertreated compared with patients without CKD 
[4, 15–18]. Furthermore, there is minimal information on 
the effects of antithrombotic management patterns (AMPs) 
on long-term outcomes beyond 1 year from the index event 
[19].
EPICOR (long-tErm follow uP of antithrombotic man-
agement patterns In acute CORonary syndrome patients, 
NCT01171404) and EPICOR Asia (NCT01361386) were 
twin observational studies of patients surviving hospitaliza-
tion for ACS who were followed-up for 2 years. The present 
analysis describes the association between long-term use of 
oral antiplatelet agents and clinical outcomes in patients with 
ACS with different degrees of renal function.
2  Materials and Methods
2.1  Patients
The EPICOR and EPICOR Asia study designs and baseline 
patient characteristics have been published previously [20, 
21]. Both were multinational, observational, prospective 
cohort studies with 2-year follow-up periods [19]. EPICOR 
enrolled patients between September 2010 and March 2011 
from 555 centers in 20 countries across Europe and Latin 
America, whereas EPICOR Asia enrolled patients between 
June 2011 and May 2012 from 218 centers in China, Hong 
Kong, India, Malaysia, Singapore, South Korea, Thailand, 
and Vietnam.
Patients who survived hospitalization for an ACS 
(STEMI, NSTEMI, or unstable angina) were eligible 
for inclusion if they were aged at least 18 years and were 
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antiplatelet agents, anticoagulants, and other cardiovascular 
medications).
2.4  Outcomes
Clinical events analyzed during follow-up were death; non-
fatal myocardial infarction (MI); nonfatal stroke; composite 
of death, MI, or stroke; first major bleeding; any bleeding; 
unstable angina; any coronary revascularization (PCI or 
CABG); and heart failure.
2.5  Statistical Analysis
Patient characteristics, AMPs, and clinical outcomes are 
summarized by eGFR category, showing the number and 
percentage of patients or mean and standard deviation for 
each variable, with p values from a chi-squared test for cat-
egorical variables or one-way analysis of variance for con-
tinuous variables used to assess differences between them; 
eGFR group was treated as a categorical variable for the 
purposes of these comparisons. Cox proportional hazards 
modeling was used to examine the association between clini-
cal outcomes (composite cardiovascular endpoint, death, 
MI, ischemic stroke, bleeding, and major bleeding) and the 
degree of renal function (eGFR 60–89, 30–59, and < 30 
with eGFR ≥ 90 mL/min/1.73  m2), estimating hazard ratios 
(HRs) and their 95% confidence interval (CI) for each out-
come. To obtain adjusted estimates of these associations, 
the Cox model was fitted containing terms for age (per 10 
years), sex, final diagnosis of index event, EQ-5D overall 
health status at discharge, in-hospital cardiac events, previ-
ous chronic obstructive pulmonary disease, previous periph-
eral vascular disease, prior PCI or CABG, admission glucose 
(< 160/≥ 160 mg/dL; cardiovascular events only), admission 
hemoglobin (< 13/≥ 13 g/dL), and diuretics at discharge, for 
subjects with data available. All p values are two-sided, with 
values < 0.05 considered statistically significant. All statisti-
cal analyses were performed using SAS version 9.3 or later.
3  Results
3.1  Patients
Of 23,490 patients enrolled in EPICOR (n = 10,568) and 
EPICOR Asia (n = 12,922), 22,380 had eGFR data available 
and were included in the present analysis. Baseline patient 
demographic and clinical characteristics are summarized by 
eGFR category in Table 1 and in eTable 1 in the electronic 
supplementary material (ESM). The majority of patients had 
eGFR ≥ 60 mL/min/1.73  m2 (41.9% eGFR ≥ 90 and 41.4% 
eGFR 60–89), whereas 16.7% had lower levels of renal func-
tion (14.5% eGFR 30–59 and 2.2% eGFR < 30). Patients 
with poorer renal function were older, with a lower level 
of education, and the percentage of male patients declined 
along with eGFR status. There were also differences across 
the country/region groups, with rates of eGFR < 30 mL/
min/1.73  m2 ranging from 1.4% in China and Eastern Europe 
to 5.6% in Thailand, Vietnam, and Malaysia. Those same 
countries/regions also had the highest and lowest rates, 
respectively, of eGFR ≥ 90 mL/min/1.73  m2. Lower renal 
function was more often associated with a higher cardio-
vascular risk profile (with the single exception of smoking) 
and a greater likelihood of prior CVD, anemia, bleeding, 
Killip class > I, lower hemoglobin, and higher blood glu-
cose levels. In the lowest eGFR group, more patients had 
NSTEMI than STEMI (46.8 vs. 37.0%). Overall, 1568 of 
11,281 (12.9%) patients with STEMI and 1438 of 6285 
(22.9%) patients with NSTEMI had CKD (eGFR < 60 mL/
min/1.73  m2).
Mean left ventricular ejection fraction (LVEF) decreased 
significantly across the four renal function groups, with an 
increasing proportion of patients with LVEF < 30% (increas-
ing from 1.6% in the highest renal function group to 8.0% in 
the lowest) (Table 1). Patients with eGFR < 60 mL/min/1.73 
 m2 were also more likely to have multiple diseased vessels 
on coronary angiography, e.g., 22.9% of patients with eGFR 
≥ 90 and 40.5% with eGFR < 30 mL/min/1.73  m2 had three 
diseased vessels and were more likely to have left main coro-
nary artery disease (11.5 and 18.8%, respectively).
3.2  Management and Outcomes
Despite presenting a higher risk, patients with CKD were 
less likely to undergo coronary angiography, PCI, or CABG 
during initial hospitalization and more likely to experience 
in-hospital cardiovascular events and bleeding (Table 2). 
Similar patterns of less aggressive management and 
increased event rates with lower eGFR were observed for 
patients in each ACS diagnostic category (eTable 2 in the 
ESM). Patients with poorer renal function were also signifi-
cantly less likely to be discharged on DAPT (aspirin plus a 
 P2Y12 inhibitor), ranging from 91.3% of patients with eGFR 
≥ 90 mL/min/1.73  m2 to 82.3% of those with eGFR < 30 
(p < 0.0001; Table 3). Patients with eGFR < 30 were also 
less likely to receive angiotensin-converting enzyme inhibi-
tor/angiotensin II receptor blockers. Similarly, patients with 
CKD were less frequently prescribed β-blockers, but more 
likely to receive anticoagulants, calcium channel blockers, 
diuretics, aldosterone inhibitors, and nitrates, whereas statin 
use was similar across the renal function groups (Table 3, 
eTable 3 in the ESM).
The average duration of DAPT ranged from 16.7 months 
in the eGFR < 30 mL/min/1.73  m2 category to 19.8 months 
in the eGFR ≥ 90 category (p < 0.0001). Use of DAPT 
during long-term follow-up declined consistently across 
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Table 1  Baseline characteristics and clinical presentation of patients with acute coronary syndrome, stratified by eGFR category at admission









Age, years 54.5 ± 9.6 63.7 ± 11.1 70.1 ± 10.4 69.7 ± 10.9 < 0.0001
Age group, years
 ≤ 59 6451 (68.8) 3291 (35.5) 514 (15.8) 90 (18.1) < 0.0001
 60–74 2783 (29.7) 4329 (46.8) 1488 (45.8) 220 (44.2)
 ≥ 75 138 (1.5) 1640 (17.7) 1248 (38.4) 188 (37.8)
Male 7619 (81.3) 6915 (74.7) 2098 (64.4) 319 (64.1) < 0.0001
eGFR, mL/min/1.73  m2b 101.9 ± 9.2 76.9 ± 8.5 48.6 ± 7.9 19.9 ± 7.6 NA
Peak creatinine, mg/dL 0.8 ± 0.2 1.0 ± 0.3 1.5 ± 0.5 3.8 ± 2.2 < 0.0001
Creatinine increase of 0.5 mg/dL or 25% 
from admission to discharge
17 (0.2) 17 (0.2) 12 (0.4) 1 (0.2) < 0.0001
BMI, kg/m2 26.0 ± 4.2 26.0 ± 4.3 25.9 ± 4.6 25.6 ± 4.7 0.317
 ≤ 25 3838 (45.0) 3758 (44.9) 1332 (46.5) 210 (50.1) 0.090
Index diagnosis < 0.0001
 STEMI 4990 (53.2) 4409 (47.6) 1384 (42.6) 184 (37.0)
 NSTEMI 2206 (23.5) 2641 (28.5) 1205 (37.1) 233 (46.8)
 Unstable angina 2176 (23.2) 2210 (23.9) 661 (20.3) 81 (16.3)
Medical history
 Hypertension 4356 (47.0) 5272 (57.5) 2337 (72.4) 417 (84.1) < 0.0001
 Diabetes 1779 (19.2) 2146 (23.5) 1094 (34.0) 262 (53.0) < 0.0001
 Hypercholesterolemia 2535 (28.1) 2923 (32.9) 1130 (36.4) 184 (39.1) < 0.0001
 Current/past smoking 6247 (68.8) 5093 (56.9) 1575 (50.2) 209 (44.7) < 0.0001
 Prior MI 939 (10.2) 1257 (13.9) 703 (22.2) 144 (29.3) < 0.0001
 Prior PCI 785 (8.5) 1034 (11.4) 502 (15.8) 96 (19.5) < 0.0001
 Prior CABG 187 (2.0) 303 (3.3) 230 (7.2) 39 (7.9) < 0.0001
 Heart failure 131 (1.4) 335 (3.79) 258 (8.1) 79 (16.1) < 0.0001
 Atrial fibrillation 105 (1.2) 319 (3.6) 199 (6.4) 37 (7.2) < 0.0001
 Stroke 246 (2.7) 483 (5.3) 274 (8.6) 47 (9.5) < 0.0001
 COPD 270 (2.9) 419 (4.6) 256 (8.0) 36 (7.3) < 0.0001
 Anemia 35 (0.4) 84 (0.9) 86 (2.7) 92 (18.6) < 0.0001
 Major bleeding within previous 6 months 35 (0.4) 41 (0.5) 30 (0.9) 9 (1.8) < 0.0001
 Killip class > I 951 (13.3) 1342 (18.6) 764 (29.1) 182 (43.7) < 0.0001
Initial laboratory measures
 Hemoglobin, g/L 141.9 (17.0) 138.6 (17.8) 130.6 (19.9) 115.4 (22.1) < 0.0001
 < 110 307 (3.3) 438 (4.8) 436 (13.9) 189 (40.0) < 0.0001
 White blood cell count, cells/µL 9919.6 ± 4492.3 9559.6 ± 4219.1 9931.7 ± 4699.0 10,581.5 ± 6662.3 < 0.0001
 Blood glucose, mg/dL 135.3 ± 59.4 139.8 ± 63.3 156.5 ± 2.7 177.3 ± 117.5 < 0.0001
In-hospital cardiac studies
 Echocardiography 7636 (81.9) 7445 (81.0) 2575 (80.0) 377 (76.5) 0.004
  Continuous LVEF measurement 6222 (66.4) 5830 (63.0) 1984 (61.1) 301 (60.4) < 0.0001
   LVEF (last pre-discharge), % 54.4 ± 11.4 52.9 ± 12.2 50.4 ± 13.3 47.2 ± 13.5 < 0.0001
   LVEF < 0.30 98 (1.6) 157 (2.7) 109 (5.5) 24 (8.0) < 0.0001
 Cardiac catheterization 8149 (87.1) 7494 (81.3) 2354 (72.7) 285 (57.3) < 0.0001
Number of diseased vessels < 0.0001
 0 537 (6.7) 457 (6.3) 154 (6.7) 15 (5.4)
 1 3484 (43.6) 2700 (37.1) 691 (30.2) 77 (27.6)
 2 2140 (26.8) 2081 (28.6) 659 (28.8) 74 (26.5)
 3 1828 (22.9) 2044 (28.1) 783 (34.2) 113 (40.5)
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the eGFR groups and declined over time (Fig. 1). At 12 
months, 57.0% of patients with eGFR < 30 mL/min/1.73  m2 
and 78.0% of those with eGFR ≥ 90 mL/min/1.73  m2 were 
still receiving DAPT. At the final follow-up visit, 38.8% of 
patients in the eGFR < 30 category continued to receive 
DAPT compared with 57.5% in the highest eGFR group. A 
similar pattern was observed across the three ACS diagnos-
tic groups (eTable 3 in the ESM).
Rates of death, nonfatal MI, nonfatal stroke, heart failure, 
and bleeding during long-term follow-up were also higher in 
patients with lower eGFR, although overall coronary revas-
cularization rates did not differ significantly between the 
categories (Table 3, eTable 3 in the ESM).
In the unadjusted proportional hazards model, there was 
a clear trend for lower eGFR levels to be associated with an 
increased risk of the composite cardiovascular endpoint and 
individual endpoints of death, MI, ischemic stroke, bleed-
ing, and major bleeding over the 2-year follow-up period 
(Fig. 2). The crude HR for all-cause death, in particular, 
was much higher when comparing patients with eGFR < 
30 versus those with eGFR ≥ 90 mL/min/1.73  m2 (10.71 
[95% CI 8.53–13.45]) than the equivalent comparison for 
patients with eGFR 60–89 mL/min/1.73  m2 (2.20 [95% CI 
1.88–2.58]). After adjustment for potential confounding fac-
tors, the HRs showed a similar consistent trend across the 
eGFR groups for all outcomes except major bleeding.
Table 1  (continued)









Left main  diseasec 918 (11.5) 915 (12.6) 393 (17.3) 51 (18.8) < 0.0001
Data are presented as mean ± standard deviation or n (%) unless otherwise indicated
BMI body mass index, CABG coronary artery bypass graft, COPD chronic obstructive pulmonary disease, eGFR estimated glomerular filtration 
rate, LVEF left ventricular ejection fraction, MI myocardial infarction, NA not applicable, NSTEMI non-ST-segment elevation MI, PCI percuta-
neous coronary intervention, STEMI ST-segment elevation MI
a p value taken from a chi-squared test (categorical variables) or one-way analysis of variance (continuous variables). eGFR group was treated as 
a categorical variable, looking at differences between the four groups
b Calculated based on initial creatinine
c Percentage of patients with data available
Table 2  In-hospital management and clinical events, stratified by eGFR category
Data are presented as n (%) unless otherwise indicated
CABG coronary artery bypass graft, eGFR estimated glomerular filtration rate, PCI percutaneous coronary intervention
a p value for trend test
b Nonfatal cardiovascular events, including those listed below this label










 Primary PCI 3540 (38.0) 3126 (34.0) 927 (28.8) 98 (19.9) < 0.0001
 Any PCI 6836 (73.4) 6161 (67.1) 1830 (56.8) 219 (44.5) < 0.0001
 Any stent 6836 (73.4) 6161 (67.1) 1830 (56.8) 219 (44.5) < 0.0001
 CABG 130 (1.4) 169 (1.8) 54 (1.7) 7 (1.4) 0.119
In-hospital outcomes
 Any cardiovascular  eventsb 1057 (11.3) 1584 (17.1) 764 (23.5) 153 (30.7) < 0.0001
  New myocardial infarction 215 (2.3) 263 (2.8) 100 (3.1) 15 (3.0) 0.035
  Heart failure or cardiogenic shock 366 (3.9) 646 (7.0) 401 (12.3) 92 (18.5) < 0.0001
  Arrhythmias 424 (4.5) 704 (7.6) 346 (10.7) 59 (11.9) < 0.0001
  Stroke 13 (0.1) 19 (0.2) 14 (0.4) 3 (0.6) 0.005
 Bleeding events 175 (1.9) 257 (2.8) 143 (4.4) 25 (5.0) < 0.0001
  Major bleeding 32 (0.3) 61 (0.7) 39 (1.2) 11 (2.2) < 0.0001
  Procedure-related bleeding 94 (1.0) 140 (1.5) 59 (1.8) 10 (2.0) < 0.001
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4  Discussion
These data from EPICOR and EPICOR Asia indicate that 
patients with renal dysfunction less frequently underwent early 
PCI or CABG and were less likely to be discharged on DAPT, 
with decreasing use across the eGFR groups as renal function 
declined. The results are in keeping with those of other studies 
[4, 15–18] and despite the known association between CKD 
and increased risk of CVD, ACS, and subsequent in-hospital 
events or death [23–26]. We also showed that in-hospital and 
long-term mortality, cardiovascular and bleeding event rates 
were higher in patients with CKD, particularly in those with 
eGFR < 30 mL/min/1.73 m2. Thus, although patients with 
poorer renal function were less likely to receive DAPT at dis-
charge and more likely to discontinue it early, they still had 
higher bleeding rates than those with “normal” renal function. 
This is the most likely reason for the apparent “undertreat-
ment” with antithrombotics in this population.
Less than 20% of the ACS survivors enrolled in these 
studies had eGFR < 60, which is somewhat lower than 
the 31–43% reported previously in the ACTION regis-
try, although it should be noted that the ACTION cohort 
included patients who died in hospital [4]. Furthermore, it 
was only in the lowest eGFR group (< 30 mL/min/1.73  m2) 
that the proportion of patients with STEMI was exceeded by 
those with NSTEMI. These discrepancies may result from 
the large and diverse population included in our cohort [27, 
28]. Overall, however, our population characteristics aligned 
with those observed elsewhere in terms of enhanced cardio-
vascular risk [1–6].
There is limited guidance on the use of PCI and antiplate-
let therapy in patients with ACS and CKD. Neither the 2013 
American College of Cardiology Foundation/American Heart 
Association (AHA) STEMI guidelines nor the 2015 Ameri-
can College of Cardiology (ACC)/AHA/Society for Cardio-
vascular Angiography and Interventions guidelines for use of 
PCI in patients with STEMI refer to renal function [29, 30]. 
European Society of Cardiology guidelines for the manage-
ment of patients with STEMI and NSTE-ACS (specifically 
referred to in the guidelines’ web-addenda) state that choice 
Table 3  Discharge medication and clinical outcomes after 2  yearsa of follow-up, stratified by eGFR category
Data are presented as n (%) unless otherwise indicated
ACEi angiotensin-converting enzyme inhibitor, ARB angiotensin II receptor blocker, CABG coronary artery bypass graft, DAPT dual antiplatelet 
therapy, eGFR estimated glomerular filtration rate, MI myocardial infarction, PCI percutaneous coronary intervention
a Final follow-up visit was at 23 months










 No antiplatelet 73 (0.8) 98 (1.1) 55 (1.7) 14 (2.8) < 0.0001
 Aspirin only 501 (5.4) 545 (5.9) 223 (6.9) 36 (7.2) 0.007
 P2Y12 inhibitor only 164 (1.8) 261 (2.8) 101 (3.1) 23 (4.6) < 0.0001
 DAPT (aspirin and  P2Y12 inhibitor) 8553 (91.3) 8210 (88.7) 2795 (86.0) 410 (82.3) < 0.0001
 Any anticoagulant 168 (1.8) 300 (3.2) 162 (5.0) 22 (4.4) < 0.0001
 ACEi/ARB 6355 (68.0) 6613 (71.6) 2280 (70.4) 258 (51.8) < 0.0001
 β-blocker 7320 (78.3) 7093 (76.8) 2439 (75.3) 366 (73.8) < 0.001
 Statin 6761 (72.3) 6835 (74.1) 2408 (74.3) 359 (72.2) 0.024
 Calcium channel blocker 1007 (10.8) 1259 (13.7) 555 (17.2) 140 (28.3) < 0.0001
 Any diuretic 854 (9.1) 1489 (16.2) 938 (29.0) 218 (44.0) < 0.0001
 Aldosterone antagonist 586 (6.3) 831 (9.0) 381 (11.8) 45 (9.1) < 0.0001
 Nitrate 316 (6.1) 421 (9.1) 170 (10.8) 44 (17.1) < 0.0001
Clinical events
 Death 227 (2.4) 484 (5.2) 403 (12.4) 110 (22.1) < 0.0001
 Nonfatal MI 186 (2.0) 239 (2.6) 138 (4.3) 30 (6.0) < 0.0001
 Nonfatal ischemic stroke 66 (0.7) 81 (0.9) 39 (1.2) 9 (1.8) 0.007
 Death/nonfatal MI/nonfatal ischemic stroke 446 (4.8) 736 (8.0) 517 (15.9) 131 (26.3) < 0.0001
 Any coronary revascularization (any PCI/CABG) 890 (9.5) 854 (9.2) 332 (10.2) 49 (9.8) 0.418
 Heart failure 295 (3.2) 537 (5.8) 337 (10.4) 73 (14.9) < 0.0001
 Any bleeding 446 (4.8) 465 (5.0) 184 (5.7) 31 (6.2) 0.130
 Major bleeding 22 (0.2) 27 (0.3) 20 (0.6) 2 (0.4) 0.010
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and dose of antithrombotic agents need to be considered care-
fully in the context of bleeding risk in patients with renal 
dysfunction, but no dose adjustment is required for aspirin 
or the  P2Y12 inhibitors clopidogrel, prasugrel, and ticagrelor 
[7, 8]. The authors of a recent meta-analysis and review of 
prasugrel or ticagrelor in patients with CKD and ACS con-
cluded that the newer antiplatelet agents were associated with 
a reduced rate of major adverse cardiovascular events com-
pared with clopidogrel, without an increased bleeding risk 
[31, 32]. AHA/ACC NSTE-ACS guidelines note that hypo-
responsiveness to clopidogrel may be an issue in patients 
with CKD and that ticagrelor may be a better alternative 
based on trial results [33]. Data from the PLATO (Platelet 
Inhibition and Patient Outcomes) trial confirmed the benefit 
of ticagrelor over clopidogrel to reduce the risk of further 
cardiovascular events in the 12 months following an ACS in 
patients with CKD [34, 35]. Nevertheless, evidence from the 
TRANSLATE-ACS (Treatment with ADP Inhibitors: Longi-
tudinal Assessment of Treatment Patterns and Events After 
Acute Coronary Syndrome) study suggested that the risk 
of moderate or severe bleeding with higher-potency  P2Y12 
inhibitors increased with the severity of CKD and that treat-
ment interruptions or a switch to clopidogrel may be more 
likely in those with more advanced disease [36].
Our analysis showed that DAPT duration during follow-
up was shorter in patients with CKD and decreased across 
the four categories of eGFR at each of the 6-month time 
points over the 2-year period, but still exceeded 12 months 
in a significant proportion of patients. A similar pattern was 
observed in the overall EPICOR and EPICOR Asia studies, 
with the majority of patients continuing to receive DAPT 
beyond 12 months [37–40]. Recent data from the large 
SWEDEHEART (Swedish Web-system for Enhancement 
and Development of Evidence-based care in Heart disease 
Evaluated According to Recommended Therapies) regis-
try showed that prolonged use of DAPT (compared with 
3 months, duration) following an ACS is associated with 
a lower risk of death, stroke, and MI in patients with or 
without CKD, with a similar bleeding risk in each case [14].
During the 2-year follow-up period in EPICOR and EPI-
COR Asia, patients with lower eGFR had higher rates of 
adverse outcomes, including death, nonfatal MI, nonfatal 
Fig. 1  Proportion of patients on 
DAPT at each visit according to 
eGFR group over 2 years. *p < 
0.0001 across eGFR categories 
at each timepoint. DAPT dual 
antiplatelet therapy, eGFR esti-
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Fig. 2  Risk of cardiovascular 
events by eGFR category, rela-
tive to eGFR ≥ 90 mL/min/1.73 
 m2, during the 2-year follow-up 
period: a eGFR < 30, b eGFR 
30–59, and c eGFR 60–89 mL/
min/1.73  m2. *Model adjusted 
for age (per 10 years), sex, final 
diagnosis of index event (UA/
STEMI/NSTEMI), EQ-5D over-
all health state at discharge, in-
hospital cardiovascular events, 
previous chronic obstructive 
pulmonary disease/lung disease, 
previous peripheral vascular 
disease, prior PCI or CABG, 
admission hemoglobin (< 
13/≥ 13 g/dL), and diuretics at 
discharge. HRs and 95% CIs 
relative to eGFR ≥ 90 mL/
min/1.73  m2,  taken from a Cox 
proportional hazards model for 
time to the endpoint in question, 
containing eGFR (< 30, 30–59, 
60–89, and ≥ 90) as a covariate. 
CABG coronary artery bypass 
graft, CI confidence interval, 
eGFR estimated glomerular 
filtration rate, EQ-5D EuroQol 
5-Dimensions, HR hazard 
ratio, MI myocardial infarction, 
NSTEMI non-ST-segment eleva-
tion myocardial infarction, PCI 
percutaneous coronary interven-
tion, STEMI ST-segment eleva-
tion myocardial infarction, UA 
unstable angina
Hazard ratio (95% CI)
HR (95% CI)eGFR <30, ml/min/1.73m2
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stroke, and bleeding. For example, 2-year mortality was 
22.1% in patients in the lowest renal function group com-
pared with 2.4% in the highest group and 5.2% in the overall 
EPICOR Asia population [41]. HRs for the composite and 
individual cardiovascular endpoints and death were higher 
in patients with poorer renal function on both unadjusted and 
adjusted analysis. Similar findings have been reported else-
where in Asian populations [42, 43]. Of note, this evidence 
is relevant because Asian populations have historically been 
under-represented in both observational and randomized 
studies [44].
There are several limitations to this analysis of data from 
the EPICOR and EPICOR Asia studies [19, 27, 37–41, 
45–52]. First, considerations inherent to the analysis of 
observational data must be taken into account, such as a 
potential patient selection bias in terms of differences in 
DAPT patterns and clinical outcomes across the eGFR 
groups. Second, the studies excluded data from non-sur-
vivors of the index event and from patients transferred to 
a non-participating hospital [45]. Another limitation is 
the lack of information on specific reasons for non-use of 
antithrombotic agents at discharge or for discontinuation of 
DAPT during long-term follow-up [38]. Third, the study did 
not track how renal function changes over time nor, there-
fore, the degree to which this impacted on further treatment 
decisions (e.g., stopping DAPT or undergoing subsequent 
intervention) or long-term outcomes. Finally, the use of 
quality indicators [52] in this patient subgroup has not been 
validated and may be challenging.
In conclusion, the presence of CKD in patients with 
ACS in the EPICOR and EPICOR Asia studies was associ-
ated with less aggressive cardiovascular management and 
an increased risk of cardiovascular events and bleeding, 
both in hospital and during long-term follow-up, with a 
consistent pattern across the three ACS diagnostic catego-
ries. Patients with ACS and renal dysfunction, therefore, 
require careful assessment and tailored short- and long-
term antithrombotic management, including selection of 
appropriate oral antiplatelet therapy, to minimize the risk 
of adverse clinical events. This recommendation may be 
particularly pertinent for patients in geographical areas 
with an apparently higher prevalence of renal dysfunction 
(Thailand/Vietnam/Malaysia and Latin America) and in 
patients with poorer socio-economic indicators, such as 
rural residence, no formal education, and lack of medical 
insurance. Future real-world evidence studies looking at 
long-term antithrombotic management strategies and out-
comes of patients with ACS should be designed to take 
such issues into consideration.
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